HEMO vs. OKYO, AOR, SAR, OPTI, AREC, POLB, RLM, NSCI, IMM, and OBD
Should you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include OKYO Pharma (OKYO), AorTech International (AOR), Sareum (SAR), OptiBiotix Health (OPTI), Arecor Therapeutics (AREC), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), NetScientific (NSCI), ImmuPharma (IMM), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry.
Hemogenyx Pharmaceuticals vs.
OKYO Pharma (LON:OKYO) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for OKYO Pharma. Hemogenyx Pharmaceuticals' average media sentiment score of 1.38 beat OKYO Pharma's score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media.
0.8% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 31.9% of OKYO Pharma shares are owned by company insiders. Comparatively, 10.7% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
OKYO Pharma has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Hemogenyx Pharmaceuticals has a beta of 3.14, indicating that its stock price is 214% more volatile than the S&P 500.
Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.
Hemogenyx Pharmaceuticals' return on equity of -80.66% beat OKYO Pharma's return on equity.
Hemogenyx Pharmaceuticals received 48 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 63.64% of users gave OKYO Pharma an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.
Summary
Hemogenyx Pharmaceuticals beats OKYO Pharma on 8 of the 12 factors compared between the two stocks.
Get Hemogenyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hemogenyx Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:HEMO) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy HEMO Stock Free HEMO Stock Alerts